Prism TPO, the fastest-growing GPO, expands specialty practice network amid rising demand for transparent drug pricing

Prism Transparent Purchasing Organization (Prism TPO) announces today the signing of its tenth independent specialty practice, marking a major milestone as more oncology practices seek clarity and simplicity in drug purchasing. The first and only transparent purchasing organization (TPO) dedicated to independent oncology, Prism TPO is seeing rapid adoption as practices move away from traditional, opaque pricing models.

The median cost of newly approved oncology drugs has reached $196,000 per annual treatment course, with gene and viral therapies often exceeding $400,000¹. While hospitals leverage 340B discounts and bulk purchasing agreements to secure better rates, independent practices face unpredictable pricing with little visibility into how costs are set. The lack of clear, public data on these disparities only deepens the challenge—leaving practices unsure if they’re paying a fair price. Prism TPO was founded to eliminate this uncertainty, providing independent practices with straightforward, transparent pricing they can trust.

"For over 25 years, I've tackled this problem from different angles," said Tesh Khullar, Founder & CEO of Prism TPO. "Now, alongside an incredible founding team, we are focusing our collective energy on achieving real change. This milestone—ten practices and growing—demonstrates that independent oncology practices are ready for a better way."

The following nine practices will begin with Prism TPO as their GPO as of April 1, 2025:

• East Texas Hematology and Oncology
• Northwest Medical Specialties
• Hope and Healing Cancer Services
• Columbus Oncology and Hematology
• Cancer and Blood Specialty Clinic
• Dayton Physicians
• Cancer Care Specialists of Illinois
• Nova Oncology
• Gabriel Domenech, M.D.

As president of ONCare Alliance, a network dedicated to empowering independent oncology practices, Dr. Sibel Blau sees transparent pricing as essential to keeping community oncology viable.

"Transparency in drug costs is not just a financial advantage—it’s a fundamental necessity for sustaining independent oncology and ensuring patients have uninterrupted access to high-quality treatments. Partnering with Prism TPO helps practices plan with confidence, eliminating the uncertainty that threatens long-term stability."

As a leader at Cancer Care Specialists of Illinois (CCSI), one of the largest independent oncology practices in the region, Justin Floyd DO, FACOI understands firsthand the challenges practices face.

"In a rapidly evolving healthcare landscape, independent oncology practices are focused on delivering the best possible patient care. In order to do so, practices also shoulder the burden of navigating a complex and at times an unpredictable drug acquisition process. Partnering with Prism TPO reduces administrative burdens, allowing a deeper focusing of administrative resources where they are most needed –our patients."

Prism TPO was founded by a team of industry veterans with decades of experience working to improve oncology care. In addition to Tesh Khullar, the leadership team includes Evan Patton, Johnny Rubino, Brian Wydra, and Lara Injeyan, all of whom bring deep experience in practice management, drug distribution, and healthcare technology.

Prism TPO is deeply connected to the oncology industry. Its partnership with several ONCare Alliance practices strengthens its ability to deliver transparent, upfront pricing to independent oncology practices while ensuring long-term sustainability for community-based cancer care.

Prism TPO will be attending the Community Oncology Conference in Orlando Florida April 29-30. For more details and to reach the team, visit PrismTPO.com

Media Contact
Prism TPO
press@prismtpo.com

¹ Moss A, Meade N, Karnuta JM, et al. Trends in the Use and Cost of Cancer Drugs in the US, 2015 to 2020. JAMA Network Open. 2024;7(1):e2352170. doi:10.1001/jamanetworkopen.2023.52170